The mission behind our iPSC stem cell research is clear: Regenerative Medical Solutions is developing a functional cure for both Type 1 and Type 2 diabetes.
Our biotechnology company was established specifically to turn Dr. Jon Odorico’s laboratory’s academic research at the University of Wisconsin into a functional diabetes cure. With a science-first approach and a world-renowned researcher at our helm, we have every confidence that our work could have a global impact.
Our diabetes cure is currently in development, offering venture capitalists the opportunity to support our work and benefit from the potential return on investment.
The Burden of Diabetes: A Global Crisis
The need for a diabetes cure is unquestionable, with 830 million people across the world affected by the disease, according to the WHO.
The majority of patients have no access to a cure, and symptom management via insulin injections is their only option. This ongoing problem also creates a devastating economic toll, and the need is growing. According to J.P. Morgan, the GLP-1 (glucagon-like peptide-1) market is projected to exceed $100 billion by 2030.
There is a gap in the market for a solution that goes beyond symptom management.
Our prospective diabetes cure is that solution, potentially eliminating insulin dependence in diabetic patients by restoring pancreatic function at the cellular level, through regenerative medicine.
RMS’s Breakthrough Diabetes Research
Our prospective diabetes cure leverages regenerative medicine to transform stem cells into insulin-producing cells, enabling diabetic patients to produce the insulin they need. This eliminates the need for insulin injections and will be a functional cure for diabetes, as it will restore patients’ own ability to produce insulin.
Our prospective diabetes treatment stands out for the following reasons:
- Our cure is safer for future patients: Anti-rejection drugs are not needed.
- Our work is ethical: We use induced pluripotent stem cells (iPSCs) instead of embryonic stem cells.
- Our treatment is scalable: It is designed for type 1 and type 2 diabetes and all blood types.
Current Status of Our Cure for Diabetes
We are progressing our iPSC-derived Islet-Like Cluster (ILC) therapy through preclinical development, with both autologous and allogeneic versions undergoing rigorous laboratory and animal model evaluation. RMS’s next milestone is a Phase I clinical trial to assess safety in human subjects.
The Investment Opportunity
The development of our new diabetes cure offers a phenomenal return on investment opportunity. Our disruptive technology has the potential to eliminate insulin dependence and offer a scalable, affordable cure for millions of diabetic patients.
Our goal to cure diabetes is backed by a strong IP portfolio, exceptional leadership team, and numerous grants received, all of which are a testament to the strong scientific evidence behind our work.
Collaborate With Us
We’re excited to bring our diabetes cure to market and invite you to be a part of our journey. If you’re a potential investor, pharmaceutical partner, or researcher looking to learn more about our cure for diabetes we welcome you to request investor materials or contact us for more information.